Evaluation of the antitumor effect of neoantigen peptide vaccines derived from the translatome of lung cancer
Cancer Immunology, Immunotherapy · 2024
DOI: 10.1007/s00262-024-03670-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Fenbao Lian und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shengli Clinical Medical College, Fujian Medical University, No. 134 East Street, Fuzhou City, 350001, Fujian Province, China. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Lung Neoplasms, Cancer Vaccines, Vaccines, Subunit. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Innovation Joint Fund Project of Fujian Province, The Key R&D Program of Xinjiang Uyghur Autonomous Region, China.
Abstract (Originalsprache)
Emerging evidence suggests that tumor-specific neoantigens are ideal targets for cancer immunotherapy. However, how to predict tumor neoantigens based on translatome data remains obscure. Through the extraction of ribosome-nascent chain complexes (RNCs) from LLC cells, followed by RNC-mRNA extraction, RNC-mRNA sequencing, and comprehensive bioinformatic analysis, we successfully identified proteins undergoing translatome and exhibiting mutations in the cells. Subsequently, novel antigens identification was analyzed by the interaction between their high affinity and the Major Histocompatibility Complex (MHC). Neoantigens immunogenicity was analyzed by enzyme-linked immunospot assay (ELISpot). Finally, in vivo experiments in mice were conducted to evaluate the antitumor effects of translatome-derived neoantigen peptides on lung cancer. The results showed that ten neoantigen peptides were identified and synthesized by translatome data from LLC cells; 8 out of the 10 neoantigens had strong immunogenicity. The neoantigen peptide vaccine group exhibited significant tumor growth inhibition effect. In conclusion, neoantigen peptide vaccine derived from the translatome of lung cancer exhibited significant tumor growth inhibition effect.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shengli Clinical Medical College, Fujian Medical University, No. 134 East Street, Fuzhou City, 350001, Fujian Province, China.
- Department of Respiratory Medicine and Critical Care Medicine, Fujian Provincial Hospital, No. 134 East Street, Fuzhou, 350001, China.
- Department of Thoracic Oncology, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, 830011, Xinjiang, China.
- Department of Breast and Thyroid Surgery, The Affiliated Tumor Hospital of Xinjiang Medical University, 789 East Suzhou Street, Xinshi District, Urumqi, 830011, Xinjiang, China. sungang@xjmu.edu.cn.
- Xinjiang Cancer Center/Key Laboratory of Oncology of Xinjiang Uyghur Autonomous Region, Urumqi, 830011, Xinjiang, China. sungang@xjmu.edu.cn.
- Shengli Clinical Medical College, Fujian Medical University, No. 134 East Street, Fuzhou City, 350001, Fujian Province, China. zgyktz@163.com.
Förderung
- Science and Technology Innovation Joint Fund Project of Fujian Province
- The Key R&D Program of Xinjiang Uyghur Autonomous Region, China
Zitieren
APA
Lian, F., Yang, H., Hong, R., Xu, H., Yu, T., Sun, G., Zheng, G., & Xie, B. (2024). Evaluation of the antitumor effect of neoantigen peptide vaccines derived from the translatome of lung cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03670-0
Vancouver
Lian F, Yang H, Hong R, Xu H, Yu T, Sun G, et al. Evaluation of the antitumor effect of neoantigen peptide vaccines derived from the translatome of lung cancer. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03670-0
BibTeX
@article{Lian2024,
author = {Lian, Fenbao and Yang, Haitao and Hong, Rujun and Xu, Hang and Yu, Tingting and Sun, Gang and Zheng, Guanying and Xie, Baosong},
title = {Evaluation of the antitumor effect of neoantigen peptide vaccines derived from the translatome of lung cancer},
journal = {Cancer Immunology, Immunotherapy},
year = {2024},
doi = {10.1007/s00262-024-03670-0}
}
EUVIMED